Skip to content
value.today

Aridis Pharmaceuticals, Inc.

Formerly Aridis Pharmaceuticals LLC

Total raised
$57 M
7 rounds on record
Latest round
$5 M
Dec 2022
First round on record
May 2014
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aridis Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$5 MNo. 7$2 to $10 million

Aridis Pharmaceuticals, Inc.: Raise no. 7, Dec 2022

Investors in this round

1 investor had bought by the notice of Dec 20, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fred Kurland · Executive Officer · Chief Financial Officer
  • Vu Truong · Executive Officer · Chief Executive Officer and Chief Scientific Officer
  • Craig Gibbs · Director · Chairman of Board of Directors
  • Eric Patzer · Director · Chairman
  • John Hamilton · Director
  • Robert Ruffolo · Director
  • Susan Windham-Bannister · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 20, 2022. Read the notice at the SEC.

equitySEC
Oct 2022$8 MNo. 6$2 to $10 million

Aridis Pharmaceuticals, Inc.: Raise no. 6, Oct 2022

Investors in this round

1 investor had bought by the notice of Oct 12, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Patzer · Executive Officer, Director · Secretary, Chairman of the Board of Directors
  • Fred Kurland · Executive Officer · Chief Financial Officer
  • Vu Truong · Executive Officer, Director · Chief Executive Officer, Director
  • Craig Gibbs · Director
  • John Hamilton · Director
  • Robert Ruffolo, Jr. · Director
  • Susan Windham-Bannister · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 12, 2022. Read the notice at the SEC.

equity, optionsSEC
Oct 2020$8 MNo. 5$2 to $10 million

Aridis Pharmaceuticals, Inc.: Raise no. 5, Oct 2020

Investors in this round

8 investors had bought by the notice of Oct 26, 2020: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$590,038
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Patzer · Executive Officer, Director · Secretary, Chairman of the Board of Directors
  • Mike Nazak · Executive Officer · Chief Financial Officer
  • Vu Troung · Executive Officer, Director · Chief Executive Officer, Director
  • Craig Gibbs · Director
  • John Hamilton · Director
  • Robert Ruffolo, Jr. · Director
  • Susan Windham-Bannister · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Arcadia Securities, LLC (CRD 44656) · New York, New YorkSold in MD, NJ
  • Cantor Fitzgerald & Co. (CRD 134) · New York, New YorkSold in MD, NJ

Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 26, 2020. Read the notice at the SEC.

equity, optionsSEC
Dec 2016$14 MNo. 4$10 to $50 million

Aridis Pharmaceuticals, Inc.: Raise no. 4, Dec 2016

Investors in this round

14 investors had bought by the notice of Dec 15, 2016: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $25 M offered; $11 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,364,270
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Patzer · Executive Officer, Director · Secretary, Chairman of the Board of Directors
  • Fred Kurland · Executive Officer · Chief Financial Officer
  • Paul-Andre de Lame · Executive Officer · Chief Medical Officer
  • Vu Troung · Executive Officer, Director · Chief Executive Officer, Director
  • Craig Gibbs · Director
  • Isaac Blech · Director · Vice Chairman
  • John Hamilton · Director
  • Robert Coughlin · Director
  • Robert Ruffolo, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Merchant Capital, a division of Maxim Group LLC (CRD 120708) · New York, New YorkSold in AL, AZ, CA, DC, FL, IL, MN, NM, NV, NY, TX

Remarks in the notice

  • On fees: “The placement agent will also recieve a warrant to purchase Series A Convertible Preferred Stock or common stock at the same exercise price as investors.”

Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 15, 2016. Read the notice at the SEC.

equity, optionsSEC
Aug 2016$15 MNo. 3$10 to $50 million

Aridis Pharmaceuticals, Inc.: Raise no. 3, Aug 2016

Investors in this round

133 investors had bought by the notice of Aug 19, 2016: 133 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $40 M offered; $25 M still to sell
Smallest investment taken
$50,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,521,624
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Patzer · Executive Officer, Director · Secretary, Chairman of the Board of Directors
  • Fred Kurland · Executive Officer · Chief Financial Officer
  • Paul-Andre de Lame · Executive Officer · Chief Medical Officer
  • Vu Truong · Executive Officer, Director · Chief Executive Officer, Director
  • Craig K. Gibbs · Director
  • Isaac R. Blech · Director · Vice Chairman
  • John K. Hamilton · Director
  • Robert K. Coughlin · Director
  • Robert R. Ruffolo, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Merchant Capital, a division of Maxim Group LLC (CRD 120708) · New York, New YorkSold in AZ, CA, CO, CT, DC, DE, FL, HI, IL, IN, KS, KY, MA, MD, MI, MN, MO, NH, NJ, NV, NY, PA, RI, SC, TX, VT, WI, WY, and outside the US

Remarks in the notice

  • On fees: “The placement agent also received a warrant to purchase Series A Convertible Preferred Stock or common stock at the same exercise price as investors.”

Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 19, 2016. Read the notice at the SEC.

equity, optionsSEC
Nov 2015$3 MNo. 2$2 to $10 million

Aridis Pharmaceuticals, Inc.: Raise no. 2, Nov 2015

Investors in this round

6 investors had bought by the notice of Nov 24, 2015: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fred Kurland · Executive Officer · Chief Financial Officer
  • Paul-Andre de Lame · Executive Officer · Chief Medical Officer
  • Vu Truong · Executive Officer, Director · Chief Executive Officer and Chief Scientific Officer
  • Craig Gibbs · Director
  • Eric Patzer · Director · Chairman of the Board of Directors
  • John Hamilton · Director
  • Robert Coughlin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Vu Truong, Chief Executive Officer and Chief Scientific Officer. Source: SEC Form D, newest notice filed Nov 24, 2015. Read the notice at the SEC.

debt, optionsSEC
May 2014$4 MNo. 1$2 to $10 million

Aridis Pharmaceuticals, Inc.: Raise no. 1, May 2014

Investors in this round

9 investors had bought by the notice of Jul 17, 2014: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$250,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: The company issued units consisting of 1 convertible note and 1 warrant
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Borgeson · Executive Officer · Chief Financial Officer (Acting)
  • Vu Truong · Executive Officer, Director · Chief Executive Officer
  • Eric Patzer · Director
  • Fred Kurland · Director
  • Robert Coughlin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric Patzer, Chairman. Source: SEC Form D, newest notice filed Jul 17, 2014. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aridis Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2022).

    SEC Form D · Dec 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2022

That is all the official record says: Aridis Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Aridis Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 133 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aridis Pharmaceuticals, Inc.
NameRoleNamed in
Fred KurlandChief Financial OfficerDec 2022
Vu TruongChief Executive Officer and Chief Scientific OfficerDec 2022
Eric PatzerSecretary, Chairman of the Board of DirectorsOct 2022
Mike NazakChief Financial OfficerOct 2020
Vu TroungChief Executive Officer, DirectorOct 2020
Paul-Andre de LameChief Medical OfficerDec 2016
John BorgesonChief Financial Officer (Acting)Jul 2014
Craig GibbsChairman of Board of DirectorsDec 2022
Eric PatzerChairmanDec 2022
John HamiltonDirectorDec 2022
Robert RuffoloDirectorDec 2022
Susan Windham-BannisterDirectorDec 2022
Robert Ruffolo, Jr.DirectorOct 2022
Vu TruongChief Executive Officer, DirectorOct 2022
Vu TroungChief Executive Officer, DirectorOct 2020
Isaac BlechVice ChairmanDec 2016
Robert CoughlinDirectorDec 2016
Craig K. GibbsDirectorAug 2016
Isaac R. BlechVice ChairmanAug 2016
John K. HamiltonDirectorAug 2016
Robert K. CoughlinDirectorAug 2016
Robert R. Ruffolo, Jr.DirectorAug 2016
Fred KurlandDirectorJul 2014